Estradiol dibutyrate
 | |
| Clinical data | |
|---|---|
| Other names | EDBu; Estradiol dibutanoate; Estradiol 3,17β-dibutanoate |
| Routes of administration | Intramuscular injection |
| Drug class | Estrogen; Estrogen ester |
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.057.990  |
| Chemical and physical data | |
| Formula | C26H35O4 |
| Molar mass | 411.562 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
Estradiol dibutyrate (EDBu), or estradiol dibutanoate, is an estrogen medication and an estrogen ester – specifically, a diester of estradiol – which is no longer used.[1][2] It was a component of Triormon Depositum, a combination formulation of estradiol dibutyrate, testosterone caproate, and hydroxyprogesterone heptanoate which was developed in the 1950s.[2]
See also
References
- ↑ Cacciari P (August 1960). "[Experimental research on estradiol dibutyrate]". Minerva Ginecol (in Italian). 12: 788–9. PMID 13689684.
- 1 2 Ermiglia, G; Valli, P (1957). "Triormon depositum in climacteric syndrome. Curves of excretion of catabolites and duration of the therapeutic effect". Quaderni Clin. Ostet. E Ginecol. 12: 284–93.
Triormon depositum (estradiol dibutyrate 3, testosterone caprylate 50, and hydroxyprogesterone heptanoate 30 mg.), administered in castor oil-benzyl benzoate soln. or polyvinylpyrrolidone suspension to 21 women in climacteric, was followed by estradiol, pregnanediol, and 17-keto steroid urinary curves, most with a peak at the 4th day, and approaching starting values at the 8-10th day. The therapeutic efficacy of the drug was satisfactory.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.